iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Torrent Pharma may have made a non-binding offer to buy a stake in Cipla

1 Sep 2023 , 02:13 PM

According to reports cited by CNBC-TV18, Cipla has received a non-binding offer from Torrent Pharma. In addition, Torrent Pharma has started investigating Cipla as part of this possible venture.

The fourth-largest domestic pharmaceutical company, Cipla, is the target of Torrent Pharma, according to reports. However, Cipla’s revenue for the fiscal year 2023 was more than twice as much as Torrent Pharma’s.

Torrent Pharma is looking into ways to form a consortium with other private equity funds, including Blackstone and Bain PE Asia-EQT among the potential partners, as well as with international institutions to ensure the realization of their strategic aspirations. This is done in an effort to possibly strengthen its position.

An earlier report had suggested that Torrent Pharma would be interested in purchasing the 33.47% stake in Cipla held by the Hamied family. According to preliminary calculations, the prospective buyer could need to make a $7.06 billion investment to obtain a 59.47% ownership.

Between itself and Cipla, Torrent Pharma has found that there is only a minimal 5% sales overlap in India. Cipla’s position in both the Indian and US markets is seen by the company—which has a market capitalization of Rs 624.09 crore—as a promising opportunity for synergy.

If the acquisition is approved, it will be the biggest Indian pharmaceutical deal in almost a decade. However, Chairman YK Hamied described any prospective developments regarding the promoter interest sale as ‘speculative’ in his speech at Cipla’s annual general meeting.

If the merger goes through, the combined company will overtake Sun Pharma as the second-largest pharmaceutical company in India in terms of revenue.

For feedback and suggestions, write to us at editorial@iifl.com

Torrent Pharmaceuticals Ltd | LinkedIn

Related Tags

  • Cipla
  • Torrent Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.